Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials

Rizzardini, Giuliano; T. Overton, Edgar; Orkin, Chloe; Swindells, Susan; Arastéh, Keikawus; Górgolas Hernández-Mora, Miguel; Pokrovsky, Vadim; Girard, Pierre-Marie; Oka, Shinichi; Andrade‐Villanueva, Jaime; Richmond, Gary; Baumgarten, Axel; Masiá, Mar; Latiff, Gulam; Griffith, Sandy; Harrington, Conn; J Hudson, Krischan; St. Clair, Marty; L. Talarico, Christine; Patel, Parul; Cutrell, Amy; Van Eygen, Veerle; D’Amico, Ronald; Mrus, Joseph; Wu, Sterling; L. Ford, Susan; Chow, Ken; Roberts, Jeremy; Wills, Angela; Walters, Nicola; Vanveggel, Simon; Van Solingen‐Ristea, Rodica; Crauwels, Herta; Y. Smith, Kimberly; Spreen, William; A. Margolis, David

doi:10.1097/qai.0000000000002466

Public

Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials

Published in JAIDS Journal of Acquired Immune Deficiency Syndromes • Aug 21, 2020

Authors:

Giuliano Rizzardini

Edgar T. Overton

Chloe Orkin

Abstract

BACKGROUND: Long-acting (LA) injectable regimens are a potential therapeutic option in people living with HIV-1. SETTING: ATLAS (NCT02951052) and FLAIR (NCT02938520) were 2 randomized, open-label, multicenter, multinational phase 3 studies. METHODS: Adult participants with virologic suppression (pla...

Subject

Rilpivirine

Medicine

Fluid-attenuated inversion recovery

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!